Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025BloodOpen Access

Multimodal epigenetic microarray classifies AML, MDS and controls using peripheral blood

View Full Paper
Ask AI
Bookmark
Share

Authors

JDJasline DeekMMMoshe MittelmanRVRoy Vitkon

Discussion

Loading...

Member takes

Overview

Analysis shows robust classification of AML and MDS using biomarkers in peripheral blood, indicating potential for improved diagnosis and monitoring.

Key Points

  • Blood samples achieved 98.3% AUC in AML vs controls, with 200 biomarkers demonstrating high sensitivity and specificity.
  • Multimodal analysis outperforms single-marker methods, indicating the advantage of integrating 5mC and 5hmC data for classification.
  • Custom microarrays targeting genomic loci enable detailed epigenetic profiling across clinical cohorts with effective discrimination.
  • Potential to enhance clinical decision-making regarding MDS monitoring and reduce reliance on invasive procedures.

Cite This Study

Deek et al. (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236da47https://doi.org/10.1182/blood-2025-3509
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1DNA methylation instability as a biomarker to predict resistance or progression to advanced disease Phase following tyrosine kinase inhibitor therapy in chronic myeloid leukemia2025
  2. 2Prognostic relevance of epigenetic regulation of drug pharmacology and myeloid genes in pediatric AML2025
  3. 3Molecular subclusters across the continuum of myelodysplastic neoplasms and acute myeloid leukaemia define distinct clinical entities2025
  4. 4Unravelling the epigenetic drivers of chip – MDS/CMML – AML progression through novel methylation-sensitive regulatory elements2025
  5. 5Epigenetic markers expand genetic risk estimation in acute myeloid leukemia2026